Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 555,642,944
  • Shares Outstanding, K 2,408,613
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,659 M
  • EBITDA $ 31,162 M
  • 60-Month Beta 0.34
  • Price/Sales 5.99
  • Price/Cash Flow 16.59
  • Price/Book 6.92

Options Overview Details

View History
  • Implied Volatility 23.56% (+0.40%)
  • Historical Volatility 14.80%
  • IV Percentile 87%
  • IV Rank 63.73%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 3) 4.17 (1.84%)
  • Put/Call Vol Ratio 1.22
  • Today's Volume 9,278
  • Volume Avg (30-Day) 20,261
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 325,622
  • Open Int (30-Day) 357,464
  • Expected Range 221.89 to 230.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 8
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
225.71 +0.08%
on 04/21/26
247.21 -8.62%
on 04/02/26
-9.47 (-4.02%)
since 03/20/26
3-Month
217.84 +3.70%
on 01/23/26
251.71 -10.25%
on 03/02/26
+7.89 (+3.62%)
since 01/21/26
52-Week
146.12 +54.60%
on 05/14/25
251.71 -10.25%
on 03/02/26
+68.98 (+43.96%)
since 04/21/25

Most Recent Stories

More News
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilities i to electrophysiology ...

JNJ : 225.14 (-2.41%)
Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

HRL : 21.41 (+0.38%)
JNJ : 225.14 (-2.41%)
KVUE : 17.43 (-0.85%)
O : 64.02 (-1.39%)
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12 th , 2026. Management will participate in a Fireside Chat at 2:20 p.m. Eastern...

JNJ : 225.14 (-2.41%)
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

JNJ stock is on track to rally higher after better-than-expected results. Cash flow and growth say this dividend story is reliable.

JNJ : 225.14 (-2.41%)
Stock Index Futures Gain on Hopes for Renewed U.S.-Iran Talks, PPI Data and More Big Bank Earnings on Tap

June S&P 500 E-Mini futures (ESM26) are up +0.19%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.39% this morning as risk appetite improved and oil prices fell following reports that the U.S. and...

BLK : 1,054.56 (+0.59%)
C : 133.08 (+0.02%)
BE : 229.03 (+4.93%)
SNDK : 908.83 (-0.46%)
CRDO : 180.30 (+3.31%)
JPM : 316.13 (-0.27%)
JNJ : 225.14 (-2.41%)
HPQ : 21.07 (+7.55%)
MU : 445.31 (-0.69%)
ORCL : 183.16 (+3.14%)
ESM26 : 7,138.25 (-0.14%)
MSFT : 425.72 (+1.83%)
Johnson & Johnson: Q1 Earnings Snapshot

Johnson & Johnson: Q1 Earnings Snapshot

JNJ : 225.14 (-2.41%)
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64 th ...

JNJ : 225.14 (-2.41%)
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter...

JNJ : 225.14 (-2.41%)
Johnson & Johnson's Innovative Medicine Momentum Meets the Reality of Double-Digit Growth Promises

Barchart Research What to Expect from JNJ Earnings JNJ Generated April 13, 2026 Current Price $237.96 EPS Estimate $$2.67 Consensus Rating Moderate Buy Average Move 2.01% Johnson & Johnson's Innovative...

JNJ : 225.14 (-2.41%)
US stocks rally and return to where they were before the US-Iran war

U.S. stocks rallied and recovered the last of their losses caused so far by the U.S.-Iran war, as hope remains on Wall Street that the global economy can still avoid a worst-case scenario

MSTR : 170.06 (-0.44%)
NFLX : 93.47 (-1.43%)
APP : 487.58 (-0.69%)
C : 133.08 (+0.02%)
BAC : 53.98 (+0.06%)
SNDK : 908.83 (-0.46%)
COP : 117.64 (+1.02%)
$SPX : 7,096.95 (-0.17%)
JPM : 316.13 (-0.27%)
JNJ : 225.14 (-2.41%)
ORCL : 183.16 (+3.14%)
GS : 932.89 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 239.85
2nd Resistance Point 237.56
1st Resistance Point 234.12
Last Price 225.14
1st Support Level 228.39
2nd Support Level 226.10
3rd Support Level 222.66

See More

52-Week High 251.71
Last Price 225.14
Fibonacci 61.8% 211.37
Fibonacci 50% 198.91
Fibonacci 38.2% 186.45
52-Week Low 146.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.